|1.||Yuki, Nobuhiro: 4 articles (08/2014 - 02/2004)|
|2.||Hirata, Koichi: 3 articles (08/2014 - 06/2012)|
|3.||Yuki, N: 3 articles (08/2006 - 05/2001)|
|4.||Zamfir, Alina D: 2 articles (07/2012 - 05/2007)|
|5.||Vukelić, Zeljka: 2 articles (07/2012 - 05/2007)|
|6.||Kalanj-Bognar, Svjetlana: 2 articles (07/2012 - 05/2007)|
|7.||Koga, Michiaki: 2 articles (07/2012 - 02/2004)|
|8.||Odaka, Masaaki: 2 articles (06/2012 - 02/2004)|
|9.||Koga, M: 2 articles (08/2006 - 05/2001)|
|10.||Hirata, K: 2 articles (08/2006 - 05/2001)|
01/15/1980 - "Incubations in vitro of GA1, labeled with 3H in the terminal D-galactopyranosyl group, with nonradioactive CMP-NeuNAc in the presence of homogenates of C21 rat brain glial cells, NIE mouse neuroblastoma cells, 3T3 mouse fibroblasts, SV 40-transformed 3T3 cells, chick embryo fibroblasts, Rous sarcoma virus-transformed chick embryo fibroblasts, and 9-day old rat brain resulted in all cases in the formation in high yield of GM1b, in which the neuraminidase-labile NeuNAc group is linked at O-3 of the terminal D-galactosyl residue, as shown by permethylation studies. "
07/01/1994 - "alpha-Neu5Gc-(2-3)-beta-D-Gal-(1-3)-beta-D-GalNac-OBn 13 isolated in 56% yield was deprotected to give the non-reducing terminal sequence of GM1b glycolylated ganglioside, which might be expressed in human tumors."
07/01/1994 - "Combined chemical and enzymatic synthesis of the sialylated non reducing terminal sequence of GM1b glycolylated ganglioside, a potential human tumor marker."
01/01/1988 - "In solid tumors, GD1a was the major ganglioside, whereas in contrast to the situation in the cultured cells, N-acetylgalactosaminyl-GD1a was almost completely absent, and ganglioside GM1b, but not GM1a, was detected. "
04/15/1979 - "Tumor ganglioside - natural occurrence of GM1b."
02/09/2007 - "The expression of GM3, presence of GD1a and GM1b in the ascitic fluid and plasma, together with a positive correlation in the total-gangliosides levels between ascitic fluid and plasma of OEC patients support the earlier contention that the tumor-gangliosides may be released (or shed) into the tumor-microenvironment. "
06/01/1997 - "This is a case of Guillain-Barré syndrome presenting with the axonal neuropathy possibly due to the immune response directed to GM1b which is triggered by the Campylobacter jejuni Penner type 4 infection."
04/01/1997 - "We speculate that an injection of bovine GM1 fraction that contains GM1b, as well as infection by an agent that bears the GM1b epitope, induces production of the anti-GM1b antibody which functions in the development of GBS in some patients."
04/01/1999 - "Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China."
05/03/1999 - "jejuni infection is closely associated with IgA antibodies, other than GM1, against GM1b. "
01/01/1998 - "We report a girl with GBS after Mycoplasma pneumoniae infection who had serum IgG antibody to GM1b ganglioside as well as the cold agglutinins. "
|4.||Miller Fisher Syndrome (Fisher Syndrome)
07/01/2012 - "These findings suggest that IgG antibodies against GM1b, GD1c, GalNAc-GM1b, and ganglioside complexes are serological markers for GQ1b-seronegative Fisher syndrome."
08/01/2006 - "Autoantibodies against GM1b and GalNAc-GD1a are associated with GBS, Fisher syndrome and related conditions. "
12/01/2002 - "In Guillain-Barré syndrome, anti GM1, GM1b, GD1a and GalNAc-GD1a antibodies are found in patients with acute motor axonal neuropathy (AMAN) and anti-GQ1b IgG antibodies are a very sensitive and specific marker for the Miller Fisher syndrome. "
|5.||Progressive Bulbar Palsy (Fazio Londe Syndrome)
04/01/1999 - "Other patients with PCB had antibody to GT1a which cross reacted with GQ1b or antibody to GM1b, but anti-GM1b and anti-GT1a antibodies were not associated with the presence of bulbar palsy. "
05/01/2001 - "Patients with diarrhea often had anti-ganglioside IgG (anti-GM1 [P=0.0006] and anti-GM1b [P=0.008]), IgM (anti-GM1 [P=0.03], anti-GM1b [P=0.02], and anti-GalNAc-GD1a [P=0.047]) antibodies and rarely showed ophthalmoparesis or bulbar palsy (respectively P=0.02, P=0.04). "
|1.||Cytidine Monophosphate (CMP)
|5.||Immunoglobulin G (IgG)
|7.||Immunoglobulin M (IgM)
|9.||ganglioside GD1alpha (GD1alpha)
|10.||asialo GM1 ganglioside